Anthropic founders put medical research at center of Nasdaq debut
Anthropic co-founders Dario and Daniela Amodei marked the company’s stock market debut by outlining how responsibly developed AI could accelerate medical breakthroughs. CEO Dario Amodei said their father died from a disease that became curable two years later, an experience that motivated their efforts to shorten research timelines and help scientists carry out complex work faster.
President Daniela Amodei said most Fortune 500 companies already use Claude in their operations. She cited teachers using the assistant to correct student papers and doctors using it to support medical diagnosis. She said AI could reduce time spent working in front of screens, freeing people to focus on more meaningful activities.
Daniela also highlighted Anthropic’s public benefit corporation structure, which requires consideration of public good alongside commercial interests. She said going public was partly intended to let more people participate in and invest in AI development. Both founders acknowledged the dangers of increasingly powerful systems. Dario said Anthropic would not compromise its safety principles under competitive or government pressure, while critics have accused the company of retreating from safety commitments following a revision to its Responsible Scaling Policy.